Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542839 · ClinicalTrials.gov registry record · NA
rTMS and Botulinum Toxin in Primary Cervical Dystonia
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT02542839 is a NA study that has completed, run by University of Florida. The registered enrollment target is 9 participants.
The verdict
NCT02542839, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Primary cervical dystonia (PCD) is the most common form of focal dystonia. PCD is frequently reported as a source of disability, decreased quality of life, and social stigma. Botulinum toxin (BoNT) is the gold standard treatment for PCD. The average duration of benefits from BoNT injections was about 9.5 weeks and BoNT treatment is known to provide only pure symptomatic benefits and does not seem to modify the disease pathophysiology. The investigator plans to use repetitive transcranial magnetic stimulation (rTMS) therapy as an adjunctive therapy in combination with BoNT injections as a novel approach to treat PCD. The primary goal of this study is to compare standard treatment with BoNT versus BoNT combined with a two week course of rTMS.
Interventions
- DEVICE NeuroStar TMS therapy
- DEVICE Sham NeuroStar TMS therapy
- OTHER Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
- OTHER Craniocervical Dystonia Questionnaire (CDQ-24)
- OTHER Cerebellar-brain Inhibition (CBI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-11 |
| Est. Completion | 2021-06-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542839
The ClinicalTrials.gov registry entry for NCT02542839 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which NeuroStar TMS therapy is the first listed.
NCT02542839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02542839 about?
NCT02542839 is a clinical study titled "rTMS and Botulinum Toxin in Primary Cervical Dystonia". Primary cervical dystonia (PCD) is the most common form of focal dystonia. PCD is frequently reported as a source of disability, decreased quality of life, and social stigma. Botulinum toxin (BoNT) is the gold standard treatment for PCD. The average duration of benefits from BoNT injections was abou...
What is the current status of trial NCT02542839?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2015-11. Estimated completion is 2021-06-28.
What interventions are being tested in trial NCT02542839?
The interventions under investigation include: NeuroStar TMS therapy (DEVICE), Sham NeuroStar TMS therapy (DEVICE), Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) (OTHER), Craniocervical Dystonia Questionnaire (CDQ-24) (OTHER), Cerebellar-brain Inhibition (CBI) (OTHER).
Who is sponsoring clinical trial NCT02542839?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.